Citations

Showing 10 of 108162 citations.

Clinical instruments for bedside functional assessment: Convergent validity among the AM‐PAC ‘6‐Clicks’ and BMAT
Lininger, Monica R. , Warren, Meghan , Knecht, Jeff, Verheijde, Joseph L., Tyler, Brenda, Tompkins, James, Lininger, Monica Rae , Verheijde, Joseph

Mayo Clinic

Journal of Clinical Nursing | April 8, 2021 | Volume: 30 | Issue: 13-14 | Pages: 2048-2056

10.1111/jocn.15761 | PMID 33829585 Get It

AbstractAims and ObjectivesTo determine the level of convergent validity of the ‘6‐Clicks’ Basic Mobility and Daily Activity with the Bedside Mobility Assessment Tool (BMAT) in patients admitted to a tertiary care academic hospital.BackgroundAccurately measuring a patient's ability to mobilise during hospitalisation is necessary but can be challenging. Two instruments, the Activity Measure for Post‐Acute Care short‐form ‘6‐Clicks’ and the BMAT, are commonly used to determine patients’ mobility levels; however, these instruments have not been psychometrically evaluated together. Understanding the characteristics between these tools can support the process of shared decision making amongst healthcare providers.DesignRetrospective Cohort adhering to the STROBE statement.MethodsUsing 13,498 individual patient admissions from an electronic health record, the BMAT score measured closest in time to the ‘6‐Clicks’ Basic Mobility and Daily Activity evaluation was collected. Spearman rank correlations with 95% confidence intervals (CIs) were calculated to determine the level of convergent validity between the ‘6‐Clicks’ Basic Mobility and Daily Activity with the BMAT. Pairwise correlations were also calculated and stratified by admitting medical service.ResultsAll correlations for the ‘6‐Clicks’ Basic Mobility or Daily Activity summative scores and the BMAT mobility levels were statistically significant and moderately correlated. The weakest correlations were seen within the Orthopaedic admitting service group. Most correlations stratified by admitting service [CVD/Pulmonary, Medicine/Hospitalist, Other Surgery and Solid Organ Transplant] were moderate. The strongest correlations were seen within the Neuro/Stroke admitting service.ConclusionModerate levels of convergent validity exist between the ‘6‐Clicks’ and the BMAT in this sample. These findings demonstrate that the construct of patient mobility is not being assessed similarly between the two instruments.Relevance to Clinical PracticeThese findings suggest the continued use of both instruments to allow interdisciplinary assessment of patient mobility status during a hospital stay.
To stent or not to stent? Treating angina after ISCHEMIA—the impact of the ISCHEMIA trial on the indications for angiography and revascularization in patients with stable coronary artery disease
Gersh, Bernard J. , Bhatt, Deepak L. , Bhatt, Deepak L , Gersh, Bernard J

Mayo Clinic

European Heart Journal | April 8, 2021 | Volume: 42 | Issue: 14 | Pages: 1389-1393

10.1093/eurheartj/ehab069.001 | PMID 33827132 Get It

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results
Advani, Ranjana H. , Moskowitz, Alison J. , Bartlett, Nancy L. , Vose, Julie M. , Ramchandren, Radhakrishnan , Feldman, Tatyana , LaCasce, Ann S. , Christian, Beth , Ansell, Stephen M. , Moskowitz, Craig H. , Ansari, Sahar , Sacchi, Mariana, Ho, Linda , Herrera, Alex F. , Bartlett, Nancy L , Advani, Ranjana H , Vose, Julie , Brown, Lisa, Zhang, Chiyu , Taft, David R. , Ansari, Sahar

Mayo Clinic

Blood | April 8, 2021 | Volume: 138 | Issue: 6 | Pages: 427-438

10.1182/blood.2020009178 | PMID 33827139 Get It

AbstractThis phase 1-2 study evaluated brentuximab vedotin (BV) combined with nivolumab (Nivo) as first salvage therapy in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). In parts 1 and 2, patients received staggered dosing of BV and Nivo in cycle 1, followed by same-day dosing in cycles 2 to 4. In part 3, both study drugs were dosed, same day, for all 4 cycles. At end of study treatment, patients could undergo autologous stem cell transplantation (ASCT) per investigator discretion. The objective response rate (ORR; N = 91) was 85%, with 67% achieving a complete response (CR). At a median follow-up of 34.3 months, the estimated progression-free survival (PFS) rate at 3 years was 77% (95% confidence interval [CI], 65% to 86%) and 91% (95% CI, 79% to 96%) for patients undergoing ASCT directly after study treatment. Overall survival at 3 years was 93% (95% CI, 85% to 97%). The most common adverse events (AEs) prior to ASCT were nausea (52%) and infusion-related reactions (43%), all grade 1 or 2. A total of 16 patients (18%) had immune-related AEs that required systemic corticosteroid treatment. Peripheral blood immune signatures were consistent with an activated T-cell response. Median gene expression of CD30 in tumors was higher in patients who responded compared with those who did not. Longer-term follow-up of BV and Nivo as a first salvage regimen shows durable efficacy and impressive PFS, especially in patients who proceeded directly to transplant, without additional toxicity concerns. This trial was registered at www.clinicaltrials.gov as #NCT02572167.
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results
Bishop, Michael R. , Oluwole, Olalekan O. , Baer, Maria R. , Donnellan, William B. , O’Dwyer, Kristen M. , Holmes, Houston, Arellano, Martha , Pagel, John M. , Lin, Yi , Park, Jae H. , Abedi, Mehrdad , Castro, Januario E. , Malone, Adriana K. , Mawad, Raya, Schiller, Gary J. , Rossi, John M. , Bot, Adrian , Shen, Tong , Goyal, Lovely, Jain, Rajul K., Vezan, Remus, Oluwole, Olalekan O , Logan, Aaron C , Cassaday, Ryan D , Castro, Januario E , Malone, Adriana K , Lin, Yi , Shah, Bijal , Bishop, Michael Russell , O'Dwyer, Kristin , Ghobadi, Armin , Cassaday, Ryan D. , DeAngelo, Daniel J. , Wierda, William G.

Mayo Clinic

Blood | April 8, 2021 | Volume: 138 | Issue: 1 | Pages: 11-22

10.1182/blood.2020009098 | PMID 33827116 Get It

Abstract ZUMA-3 is a phase 1/2 study evaluating KTE-X19, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). We report the phase 1 results. After fludarabine-cyclophosphamide lymphodepletion, patients received a single infusion of KTE-X19 at 2 × 106, 1 × 106, or 0.5 × 106 cells per kg. The rate of dose-limiting toxicities (DLTs) within 28 days after KTE-X19 infusion was the primary end point. KTE-X19 was manufactured for 54 enrolled patients and administered to 45 (median age, 46 years; range, 18-77 years). No DLTs occurred in the DLT-evaluable cohort. Grade ≥3 cytokine release syndrome (CRS) and neurologic events (NEs) occurred in 31% and 38% of patients, respectively. To optimize the risk-benefit ratio, revised adverse event (AE) management for CRS and NEs (earlier steroid use for NEs and tocilizumab only for CRS) was evaluated at 1 × 106 cells per kg KTE-X19. In the 9 patients treated under revised AE management, 33% had grade 3 CRS and 11% had grade 3 NEs, with no grade 4 or 5 NEs. The overall complete remission rate correlated with CAR T-cell expansion and was 83% in patients treated with 1 × 106 cells per kg and 69% in all patients. Minimal residual disease was undetectable in all responding patients. At a median follow-up of 22.1 months (range, 7.1-36.1 months), the median duration of remission was 17.6 months (95% confidence interval [CI], 5.8-17.6 months) in patients treated with 1 × 106 cells per kg and 14.5 months (95% CI, 5.8-18.1 months) in all patients. KTE-X19 treatment provided a high response rate and tolerable safety in adults with R/R B-ALL. Phase 2 is ongoing at 1 × 106 cells per kg with revised AE management. This trial is registered at www.clinicaltrials.gov as #NCT02614066.
Morphologic and Molecular Findings in Myxoid Hepatic Adenomas
Yasir, Saba , Chen, Zongming E., Mounajjed, Taofic, Damgard, Sibel Erdogan, Cummins, Lisa, Zhang, Lizhi , Whitcomb, Emma, Falck, Vince, Simon, Sanford M. , Rowan, Daniel J. , Erdogan Damgard, Sibel, Simon, Sanford M , Cummins, Lisa, Falck, Vincent, Singhi, Aatur Dilip , Torbenson, Michael

Mayo Clinic

American Journal of Surgical Pathology | April 8, 2021 | Volume: 45 | Issue: 8 | Pages: 1098-1107

10.1097/pas.0000000000001711 | PMID 34232602 Get It

Myxoid hepatic adenomas are a rare subtype of hepatic adenomas with distinctive deposition of extracellular myxoid material between the hepatic plates. A total of 9 cases were identified in 6 women and 3 men with an average of 59±12 years. The myxoid adenomas were single tumors in 5 cases and multiple in 4 cases. In 1 case with multiple adenomas, the myxoid adenoma arose in the background of GNAS-mutated hepatic adenomatosis. Myxoid hepatic adenomas had a high frequency of malignant transformation (N=5 cases). They were characterized at the molecular level by HNF1A inactivating mutations, leading to loss of LFABP protein expression. In addition, myxoid adenomas had recurrent mutations in genes within the protein kinase A (PKA) pathway or in genes that regulate the PKA pathway: GNAS, CDKN1B (encodes p27), and RNF123. In sum, myxoid adenomas are rare, occur in older-aged persons, have a high risk of malignant transformation, and are characterized by the combined inactivation of HNF1A and additional mutations that appear to cluster in the PKA pathway.
Clinical Presentation, Management, and Outcomes of Patients With Brain Abscess due to Nocardia Species
Campioli, Cristina Corsini , Almeida, Natalia E. Castillo , Go, John Raymond , Corsini Campioli, Cristina , Castillo Almeida, Natalia E, O'Horo, John C, Go, J Raymond , Castillo, Natalia E , O’Horo, John C. , Challener, Douglas W. , DeSimone, Daniel C. , Sohail, M. Rizwan

Mayo Clinic

Open Forum Infectious Diseases | April 8, 2021 | Volume: 8 | Issue: 4 | Pages: No page available

10.1093/ofid/ofab067 | PMID 33855101 Get It

Abstract Background Nocardial brain abscesses are rare, and published literature describing brain abscesses due to Nocardia species is limited to individual case reports or small series. We report one of the largest contemporary retrospective studies describing risk factors, diagnostic evaluation, management, and outcomes of nocardial brain abscess. Methods Retrospective review of all adults with brain abscess due to culture-confirmed Nocardia species at our institution between January 1, 2009, and June 30, 2020. Results Overall, 24 patients had nocardial brain abscesses during the study period. The median age at presentation was 64 years, and 62.5% were immunocompromised. Pulmonary and cutaneous infections were the most common primary sites of nocardial infection. All 24 patients had magnetic resonance imaging performed, and the frontal lobe was the most commonly involved. The most common organism isolated was Nocardia farcinica, followed by Nocardia wallacei and Nocardia cyriacigeorgica. Thirteen patients were managed with antimicrobial therapy alone, while 11 had both medical and surgical management. In all patients, dual therapy was recommended for the initial 6 weeks of treatment, and 22 patients received at least 1 oral agent as part of their final antibiotic regimen, predominantly trimethoprim-sulfamethoxazole and linezolid. Fourteen patients achieved complete clinical and radiographic resolution of infection. Conclusions Nocardia is an important cause of brain abscess in the immunocompromised host. Early diagnostic and therapeutic aspiration may help health care providers confirm the diagnosis, choose an appropriate antimicrobial regimen, and achieve source control.
Prognostic and therapeutic value of the Hippo pathway, RABL6A, and p53-MDM2 axes in sarcomas
Thomason, Jon, Kohlmeyer, Jordan L. , Reisetter, Anna C. , Ahirwar, Parmanand , Jahanseir, Khadijeh, Leidinger, Mariah , Ofori‐Amanfo, Georgina, Fritchie, Karen , Breheny, Patrick , Tanas, Munir R. , Desai, Chandni, Velu, Sadanandan E. , Quelle, Dawn E.

Mayo Clinic

Oncotarget | April 7, 2021 | Volume: 12 | Issue: 8 | Pages: 740-755

10.18632/oncotarget.27928 | PMID 33889298 Get It

Hospitalist perspectives on barriers to recommend and potential benefit of the COVID-19 vaccine
Dugani, Sagar B. , Geyer, Holly L. , Maniaci, Michael J. , Fischer, Karen M. , Croghan, Ivana T. , Coons, Trevor J. , Canan, Elizabeth L. , Burton, M. Caroline , Fischer, Karen M , Coons, Trevor , Maniaci, Michael J , Dugani, Sagar B

Mayo Clinic

Hospital Practice | April 7, 2021 | Volume: 49 | Issue: 4 | Pages: 245-251

10.1080/21548331.2021.1914465 | PMID 33826433 Get It

In Reply
Huober, Jens , Masuda, Norikazu , Sohn, Joohyuk , Barriga, Susana , Cox, Joanne, Rugo, Hope S , Masuda, Norikazu , Sohn, Joohyuk , Rugo, Hope S. , García-Sáenz, José Á. , André, Valérie , Goetz, Matthew P.

Mayo Clinic

The Oncologist | April 7, 2021 | Volume: 26 | Issue: 7 | Pages: e1286-e1287

10.1002/onco.13782 | PMID 33826783 Get It

This letter to the editor responds to Badoui et al. regarding data on abemaciclib dosages and adverse events.
A Yet Unrealized Promise: Structured Advance Care Planning Elements in the Electronic Health Record
Gundersen, Daniel A. , Paasche‐Orlow, Michael K. , Tulsky, James A. , Brannen, Elise N. , Kennedy, Danielle , McLeggon, Jody‐Ann , Stout, Jeremiah , Volandes, Angelo E., Investigators, The ACP-PEACE, Carney, Maria Torroella , Martins-Welch, Diana , Chan, Camille , Qiu, Michael , Tilburt, Jon C. , Loprinzi, Charles L. , Rahman, Parvez, Davis, Aretha Delight , El‐Jawahri, Areej , Stout, Jeremiah J, Lakin, Joshua R. , Lindvall, Charlotta , Pollak, Kathryn I. , Investigators, The ACP-PEACE, Zafar, S. Yousuf , Devoe, Craig

Mayo Clinic

Journal of Palliative Medicine | April 7, 2021 | Volume: 24 | Issue: 8 | Pages: 1221-1225

10.1089/jpm.2020.0774 | PMID 33826860 Get It

Background: Electronic health records (EHRs) may help enable reliable, rapid data management for many uses, such as facilitating communication of advance care planning (ACP). However, issues with validity and accuracy of EHRs hinder the use of ACP information for practical applications. Design: We present a cross-sectional pilot study of 433 older adults with cancer from three large health care systems, participating in an ongoing multisite pragmatic trial (4UH3AG060626-02). We compared data extracted from dedicated structured EHR fields for ACP to a chart review of corresponding ACP documentation contained in the medical chart. Results: Structured ACP data existed for 43.2% of patients and varied by site (25.7% −48.9%). Of the identified structured ACP data elements, 59.2% of recorded elements were correct, 23.7% were incorrect, and 17.1% were duplicates with heterogeneity across sites. Conclusion: Structured ACP data in EHRs were frequently incorrect. This represents a problem for patients and their families, as well as quality improvement and research efforts. Clinical Trials Registration: NCT03609177.